Results 41 to 50 of about 3,657 (146)
Primaquine radical cure of
Malaria Journal, 2012 Background Primaquine has been the only widely available hypnozoitocidal anti-malarial drug for half a century. Despite this its clinical efficacy is poorly characterized resulting in a lack of consensus over the optimal regimen for the radical cure of ...
John George K +6 more
doaj +1 more source
CYP2D6 Allele Frequency in Five Malaria Vivax Endemic Areas From Brazilian Amazon Region
Frontiers in Pharmacology, 2021 Genetic variability was linked with individual responses to treatment and susceptibility to malaria by Plasmodium vivax. Polymorphisms in the CYP2D6 gene may modulate enzyme level and activity, thereby affecting individual responses to pharmacological ...
Paula Ferreira Salles +11 more
doaj +1 more source
PLoS Neglected Tropical Diseases, 2017 BackgroundPrimaquine is the only licensed antimalarial for the radical cure of Plasmodium vivax infections. Many countries, however, do not administer primaquine due to fear of hemolysis in those with glucose-6-phosphate dehydrogenase (G6PD) deficiency ...
Angela Devine +7 more
doaj +1 more source
G6PD Variants and Haemolytic Sensitivity to Primaquine and Other Drugs
Frontiers in Pharmacology, 2021 Restrictions on the cultivation and ingestion of fava beans were first reported as early as the fifth century BC. Not until the late 19th century were clinical descriptions of fava-induced disease reported and soon after characterised as “favism” in the ...
Germana Bancone +3 more
doaj +1 more source
Safety and efficacy of single-dose primaquine to interrupt Plasmodium falciparum malaria transmission in children compared with adults: a systematic review and individual patient data meta-analysis [PDF]
Background: Adding a single dose of primaquine to artemisinin-based combination therapy (ACT) for the treatment of falciparum malaria can reduce the transmission of Plasmodium falciparum and could limit the spread of artemisinin partial resistance ...
WWARN Paediatric Primaquine for P falciparum Transmission Blocking Study Group +15 more
core +1 more source
Relapse of imported
Malaria Journal, 2012 Background Relapsing Plasmodium vivax infection results in significant morbidity for the individual and is a key factor in transmission. Primaquine remains the only licensed drug for prevention of relapse.
Townell Nicola +3 more
doaj +1 more source
Primaquine for uncomplicated Plasmodium vivax malaria in children younger than 15 years: a systematic review and individual patient data meta-analysis. [PDF]
BACKGROUND: Primaquine, the only widely available treatment to prevent relapsing Plasmodium vivax malaria, is produced as 15 mg tablets, and new paediatric formulations are being developed. To inform the optimal primaquine dosing regimen for children, we
Brasil, Larissa W +42 more
core +1 more source
Reinventing primaquine for endemic malaria. [PDF]
, 2012 After sixty years of continuous use, primaquine remains the only therapy licensed for arresting transmission and relapse of malaria. The US Army developed primaquine for soldiers in a wartime crisis setting.
Baird, JK, Baird, John, Baird, J. Kevin
core +1 more source
Wellcome Open Research, 2019 Radical cure of Plasmodium vivax malaria in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals employs weekly primaquine dosing. This is the only recommended regimen for this patient sub-group.
Cindy S. Chu +5 more
doaj +1 more source
Journal of Infection in Developing Countries, 2023 Hyperparasitaemia is an important event in the cascade of Plasmodium falciparum severe malaria (SM), and may also lead to SM associated complications and death, if left untreated.
Benudhar Mukhi +5 more
doaj +1 more source